{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:40:08Z","timestamp":1749505208708,"version":"3.41.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:sec>\n            <jats:title>Object:<\/jats:title>\n            <jats:p>Effective treatment of neuromyelitis optica spectrum disorder (NMOSD) can greatly reduce the rate of disability and mortality among patients. NMOSD treatment studies are gaining prominence in academic circles. This study aims to depict the evolution and integration of NMOSD treatment over the past 20 years, identify key contributors in the field, clarify current research hotspots, and explore emerging topics that may guide future research directions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>Articles in this field from 2004 to 2023 were collected from the Web of Science Core Collection (WoSCC). After conducting a literature search, a comprehensive bibliometric and knowledge mapping analysis was carried out on the retrieved articles using tools such as VOSviewer, Bibliometrix, and CiteSpace.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result:<\/jats:title>\n            <jats:p>The rapid growth in annual publications in this field indicates rapid progress and innovation. USA, Mayo Clinic, and Fujihara K led in productivity and impact, while the multiple sclerosis and related disorders topped in publication volume. The research hotspots in this field mainly focus on targeted biological agents. Additionally, this study has identified 3 emerging themes and conducted an in-depth exploration of their future development trends.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In summary, this bibliometric analysis provides for the first time a comprehensive framework and frontier hot spot analysis in the field of NMOSD treatment, offering references for researchers in the field and contributing to the further development of the field.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042850","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:45Z","timestamp":1749502965000},"page":"e42850","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Research hotspots and emerging topics in neuromyelitis optica spectrum disorder treatment: Insights from a bibliometric analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Juan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Yancheng Maternal and Child Health Care Hospital Affiliated to Yangzhou University, Yancheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbiao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yancheng Maternal and Child Health Care Hospital Affiliated to Yangzhou University, Yancheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nantong University Medical College, Nantong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Qin","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Yancheng No. 1 People\u2019s Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China"},{"name":"Department of Pediatrics, The First People\u2019s Hospital of Yancheng, Yancheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-2455","authenticated-orcid":false,"given":"Ben","family":"Liu","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Yancheng No. 1 People\u2019s Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China"},{"name":"Pediatric Intensive Care Unit, The First People\u2019s Hospital of Yancheng, Yancheng, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum.","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1007\/s00415-024-12426-w","article-title":"Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.","volume":"271","author":"P","year":"2024","journal-title":"J Neurol"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11910-023-01287-x","article-title":"A clinical approach to existing and emerging therapeutics in neuromyelitis optica spectrum disorder.","volume":"23","author":"Yong","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"1463078","DOI":"10.3389\/fimmu.2024.1463078","article-title":"Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis.","volume":"15","author":"Tu","year":"2024","journal-title":"Front Immunol"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10571-024-01484-3","article-title":"A bibliometric analysis of the spatial transcriptomics literature from 2006 to 2023.","volume":"44","author":"Zhao","year":"2024","journal-title":"Cell Mol Neurobiol"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial.","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder.","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica.","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7_Supplement_1","key":"R16-20250609","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/01.wnl.0001051032.57644.0a","article-title":"Socioeconomic factors associated with \u22652-year delayed diagnosis of neuromyelitis optica spectrum disorder (NMOSD) in the United States.","volume":"103","author":"Blackowicz","year":"2024","journal-title":"Neurology"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management.","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.3390\/ijms21145021","article-title":"Differential effects of MS therapeutics on B cells-implications for their use and failure in AQP4-Positive NMOSD patients.","volume":"21","author":"Traub","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.12998\/wjcc.v12.i30.6361","article-title":"Overview of emerging therapies for demyelinating diseases.","volume":"12","author":"Medina","year":"2024","journal-title":"World J Clin Cases"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurol.2024.01.008","article-title":"Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies.","volume":"181","author":"Demuth","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder.","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial.","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult Scler"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11910-024-01366-7","article-title":"B-cell depletion therapy in pediatric neuroinflammatory disease.","volume":"24","author":"Wu","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"e30347","DOI":"10.1097\/MD.0000000000030347","article-title":"A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.","volume":"101","author":"Dong","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease.","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"R27-20250609","doi-asserted-by":"crossref","first-page":"e200071","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar.","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R28-20250609","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term safety and efficacy of eculizumab in Aquaporin-4 IgG-Positive NMOSD.","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"R29-20250609","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14712598.2024.2423002","article-title":"An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder.","volume":"24","author":"Balaban","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"R30-20250609","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728214.2022.2059463","article-title":"Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients.","volume":"27","author":"Carnero Contentti","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"key":"R31-20250609","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jnnp-2024-334090","article-title":"Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: a multicentre study.","volume":"96","author":"Siriratnam","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R32-20250609","doi-asserted-by":"crossref","first-page":"933415","DOI":"10.3389\/fimmu.2022.933415","article-title":"Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: how it influences clinical course, MRI parameters and prognosis.","volume":"13","author":"Nytrova","year":"2022","journal-title":"Front Immunol"},{"key":"R33-20250609","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","article-title":"Immunosuppressive drugs and fertility.","volume":"10","author":"Leroy","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R34-20250609","doi-asserted-by":"crossref","first-page":"102525","DOI":"10.1016\/j.autrev.2020.102525","article-title":"In utero exposure to Azathioprine in autoimmune disease. Where do we stand?","volume":"19","author":"Belizna","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R35-20250609","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice.","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20250609","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany.","volume":"8","author":"K\u00fcmpfel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R37-20250609","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/acn3.51683","article-title":"Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.","volume":"9","author":"Du","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R38-20250609","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/13524585221130934","article-title":"Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.","volume":"29","author":"Vukusic","year":"2023","journal-title":"Mult Scler"},{"key":"R39-20250609","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","article-title":"A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes.","volume":"43","author":"Bandoli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"R40-20250609","doi-asserted-by":"crossref","first-page":"104760","DOI":"10.1016\/j.msard.2023.104760","article-title":"A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).","volume":"75","author":"Leite","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R41-20250609","doi-asserted-by":"crossref","first-page":"101051","DOI":"10.1016\/j.spen.2023.101051","article-title":"Pediatric neuromyelitis optica spectrum disorder.","volume":"46","author":"Poisson","year":"2023","journal-title":"Semin Pediatr Neurol"},{"key":"R42-20250609","doi-asserted-by":"crossref","first-page":"1257955","DOI":"10.3389\/fimmu.2023.1257955","article-title":"Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R43-20250609","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1007\/s00415-023-11776-1","article-title":"Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.","volume":"270","author":"Wang","year":"2023","journal-title":"J Neurol"},{"key":"R44-20250609","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker.","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"key":"R45-20250609","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R46-20250609","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/jnnp-2022-328956","article-title":"MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD.","volume":"93","author":"Cacciaguerra","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:52Z","timestamp":1749502972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":46,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042850","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}